The construction of large-scale peptidomimetic libraries for drug screening of metabolic diseases is of great significance for the treatment of metabolic diseases. CD BioSciences provides peptidomimetic library construction and drug screening services for a variety of metabolic diseases, assisting global customers in basic research and drug discovery for related disease treatments.
Overview of Metabolic Diseases
With the development of the economy, the prevalence of metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), fatty liver and other metabolic diseases has shown a rapid upward trend worldwide. These metabolic diseases can further develop into cardiovascular diseases (CVDs), such as atherosclerosis, hypertension, coronary heart disease, etc., which are closely related to the occurrence and development of cancer.
Fig. 1 Putative pathways of progression from innate to adaptive immune responses in obesity and type 2 diabetes mellitus. (Velloso,et al., 2013)
Cause and Treatment of Metabolic Diseases
Metabolic diseases occur in several different ways:
- Inheritance - Many metabolic diseases are passed from parents to their children at birth.
- Hormone deficiency - An imbalance or deficiency of one or more of the hormones.
- Organ problems or failure - Metabolic disorders can occur when organs involved in metabolic processes stop functioning properly.
Currently, peptide drugs are widely used in the treatment of metabolic diseases, but their shortcomings such as poor stability and low bioavailability limit their further treatment and development possibilities. Searching for new peptidomimetic drugs to make up for the above shortcomings has been widely concerned by medical researchers.
Common Types of Metabolic Diseases
- T2DM is one of the most common metabolic diseases (MDS), characterized by elevated blood glucose concentration, which is a chronic disease caused by lifestyle and affects millions of people worldwide.
- Obesity is an independent risk factor for type 2 diabetes, which can aggravate insulin resistance. The World Health Organization estimates that the number of obese adults has increased more than sevenfold in the past 40 years.
- Hyperlipidemia and atherosclerosis are the main risk factors of type 2 diabetes, accompanied by energy imbalance, insulin resistance and fat accumulation.
- Gout is one of the most common inflammatory arthritis in the world, caused by long-term hyperuricemia and the formation of monosodium urate (MSU) crystals and is closely related to cardiovascular disease and chronic kidney disease.
- Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease, with about 17-51% of adults worldwide suffering from NAFLD.
Our Services
In CD BioSciences, in addition to providing specialized peptidomimetic development services for metabolic targets, we can also use our advanced PepDomTM platform to build a high-throughput peptidomimetic screening library to screen drugs related to metabolic diseases through phenotypic analysis.
The types of metabolic diseases we focus on include, but are not limited to:
- Diabetes
- Gaucher Disease
- Hunter Syndrome
- Maple Syrup Urine Disease
- Phenylketonuria
- Tay Sachs Disease
- Wilson's Disease
- Others
Our Service Processes
Advantages of Our Service
 |
The peptidomimetic library sequences and lengths can be customized. |
 |
The cycle is short, and the phenotype screening is realized by direct incubation of the library. |
 |
The verification is done after screening, which guarantees the reliability of the results. |
By building a high-throughput peptidomimetic screening platform, CD BioSciences is committed to screening drugs for the treatment of various metabolic diseases. If you are interested in our services, please contact us for the best solution.
Reference
- Velloso, L. A., Eizirik, D. L., & Cnop, M. (2013). Type 2 diabetes mellitus—an autoimmune disease? Nature Reviews Endocrinology, 9(12), 750–755.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
